State of Wyoming Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Wyoming increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.6% during the 4th quarter, HoldingsChannel reports. The firm owned 14,068 shares of the biopharmaceutical company’s stock after buying an additional 3,691 shares during the period. State of Wyoming’s holdings in Halozyme Therapeutics were worth $673,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 197 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after acquiring an additional 200 shares during the last quarter. Baird Financial Group Inc. boosted its stake in shares of Halozyme Therapeutics by 2.0% during the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company’s stock worth $532,000 after acquiring an additional 221 shares during the last quarter. CreativeOne Wealth LLC boosted its stake in shares of Halozyme Therapeutics by 1.6% during the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company’s stock worth $879,000 after acquiring an additional 294 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after acquiring an additional 302 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This trade represents a 0.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company’s stock, valued at $1,972,629.59. The trade was a 12.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,697 shares of company stock worth $1,276,552. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HALO. HC Wainwright reiterated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Leerink Partners downgraded shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research report on Tuesday, May 13th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 13th. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Finally, Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $61.90.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $52.02 on Monday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market cap of $6.41 billion, a P/E ratio of 15.17, a P/E/G ratio of 0.42 and a beta of 1.26. The firm’s fifty day moving average is $60.69 and its two-hundred day moving average is $55.98. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Halozyme Therapeutics’s revenue for the quarter was up 35.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.79 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.